Pediatric implications of COVID and 'vaccines'



Dr. Elizabeth Mumper, MD, FAAP, IFMCP Founder and CEO, Rimland Center for Integrative Medicine President and CEO, Advocates for Families Former Medical Director, Autism Research Institute

www.flccc.net/drliz

Cassandra


Best-known for her prophetic powers, within Greek mythology Cassandra is a princess of Troy who lived during the era of the Trojan War.

Her gift of prophecy, however, was accompanied by a curse – no one believed in her prophecies, making her powerless to stop fate from running its course.




Lissandra: Written August 2020





Lissandra June 2021





I CARE treatment guidelines for children now available FLCCC website Series of short videos about children's health





Background experience dealing with chronic conditions in children

134

Jul 2013 Vol 6 No. 3

North American Joannal of Medicine and Science

Original Research

Can Awareness of Medical Pathophysiology in Autism Lead to Primary Care Autism Prevention Strategies?

Elizabeth Mumper, MD, FAAP*

2919 Confederate Avenue, Lynchburg, VA

Emerging research suggests that the timing of environmental factors in the presence of genetic predispositions has influenced the increase in autism spectrum disorders over the past several decades. A review of the medical literature suggests that autism may be impacted by environmental toxicants, breastfeeding duration, gut flora composition, nutritional status, acetaminophen use, vaccine practices and use of antibiotics and/or frequency of infections. The author reports her retrospective clinical research in a general pediatric practice (Advocates for Children), which shows a modest trend toward lower prevalence of autism than her previous pediatric practice or recent CDC data. Out of 294 general pediatrics patients followed since 2005 there were zero new cases of autism (p value 0.014). Given the prevalence of autism for that cohort of 1 in 50 children in the United States, it is important to consider implementing strategies in primary care practice that could potentially modify environmental factors or affect the timing of environmental triggers contributing to autism.

[N A J Med Sci. 2013;6(3):134-144. DOI: 10.7156/najms.2013.0603134]

Key Words: primary care, autism, prevention strategies

Of 294 inborn patients, none developed autism

Background rate:
1 in 50 US
vs 1 in 297 Mumper

P value 0.014

Latest data from CDC:

1 in 36 children

1 in 22 males

1 in 10 Black/Hispanic
(birth cohort 2012)

Analysis of Results: 4821 pediatric patients

Diagnosis	Vaccinated Cases/Total	Unvaccinated Cases/Total	Odds Ratio (95% CI)	P-value	
Developmental Delay	153/1407 (10.9%)	34/630 (5.4%)	2.18 (1.47 – 3.24)	0.0001	
Asthma	67/1412 (4.7%)	7/629 (1.1%)	4.49 (2.04 – 9.88)	0.0002	
Ear Infection	324/1116 (29.0%)	104/533 (19.5%)	2.13 (1.63 – 2.78)	<0.0001	
Gastrointestinal Disorder	55/1382 (4.0%)	18/619 (2.9%)	1.47 (0.84 – 2.57)	0.17	
Head Injury	93/1398 (6.7%)	31/627 (4.9%)	1.26 (0.82 – 1.94)	0.29	

Number of Vaccines by Quartile

Diagnosis	Quartile 1 1-5 Vaccines (95% CI)	Quartile 2 6-10 Vaccines (95% CI)	Quartile 3 11-12 Vaccines (95% CI)	Quartile 4 13-21 Vaccines (95% CI)
Developmental Delay	1.36 (0.53 – 3.48)	2.54 (1.30 – 4.96)	3.22 (1.70 – 6.09)	2.42 (1.17 – 4.99)
Asthma	1.94 (0.59 – 6.40)	6.48 (2.64 – 15.9)	3.66 (1.42 – 9.46)	4.62 (1.68 – 12.7)
Ear Infection	1.43 (0.98 – 2.07)	2.48 (1.72 – 3.60)	2.26 (1.53 – 3.33)	2.81 (1.80 – 4.40)
Gastrointestinal Disorder	0.49 (0.19 – 1.31)	1.61 (0.68 – 3.84)	3.77 (1.65 – 8.59)	4.03 (1.57 – 10.3)
Head Injury	0.68 (0.32 – 1.44)	1.56 (0.93 – 2.62)	1.12 (0.65 – 1.94)	1.37 (0.73 – 2.56)

Analysis of health outcomes in vaccinated and unvaccinated children: Developmental delays, asthma, ear infections and gastrointestinal disorders

SAGE Open Medicine
Volume 8: I-II

The Author(s) 2020
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/2050312120925344
journals.sagepub.com/horne/smo

SSAGE

Brian S Hooker 100 and Neil Z Miller2

Abstract

Objective: The aim of this study was to compare the health of vaccinated versus unvaccinated pediatric populations. Methods: Using data from three medical practices in the United States with children born between November 2005 and June 2015, vaccinated children were compared to unvaccinated children during the first year of life for later incidence of developmental delays, asthma, ear infections and gastrointestinal disorders. All diagnoses utilized International Classification of Diseases–9 and International Classification of Diseases–10 codes through medical chart review. Subjects were a minimum of 3 years of age, stratified based on medical practice, year of birth and gender and compared using a logistic regression model. Results: Vaccination before I year of age was associated with increased odds of developmental delays (OR=2.18, 95% CI 1.47–3.24), asthma (OR=4.49, 95% CI 2.04–9.88) and ear infections (OR=2.13, 95% CI 1.63–2.78). In a quartile analysis,

subjects were grouped by number of vaccine doses received in the first year of life. Higher odds ratios were observed in Quartiles 3 and 4 (where more vaccine doses were received) for all four health conditions considered, as compared to Quartile 1. In a temporal analysis, developmental delays showed a linear increase as the age cut-offs increased from 6 to 12 to 18 to 24months of age (ORs = 1.95, 2.18, 2.92 and 3.51, respectively). Slightly higher ORs were also observed for all four

health conditions when time permitted for a diagnosis was extended from \geq 3 years of age to \geq 5 years of age. Conclusion: In this study, which only allowed for the calculation of unadjusted observational associations, higher ORs were observed within the vaccinated versus unvaccinated group for developmental delays, asthma and ear infections. Further study is necessary to understand the full spectrum of health effects associated with childhood vaccination.

Keywords

Vaccination, developmental delays, asthma, ear infections, gastrointestinal disorders

Date received: 18 June 2019; accepted: 20 April 2020


FIRST, DO NO HARM






Suicide Ideation and Attempts in a Pediatric ER Before and During COVID-19"

- Suicide attempts began rising in February 2020
- In March suicide attempts were double the previous year
- Attempts stayed elevated through the summer





The Biology of Trauma

The brain is not structurally complete at birth.

- Myelination, proliferation of synaptic connections, then pruning and development of glial and circulatory support systems all continue long after a child has entered the world.
- Nature gives children a chance to adapt to the specific needs presented by the environment into which they have been born.
 - Opportunities for optimal development:
 - Adequate nutrition vs. school closures during COVID
 - Avoidance of toxins like lead, mercury, alcohol, artificial spike proteins
 - Nurturing, loving and stimulating environment
 - Development of the ability to "read" faces
 - Caregivers present, attentive and consistent vs. COVID trauma to adult population

Brown University Study

Impact of the COVID-19 Pandemic on Early Child Cognitive Development: Initial Findings in a Longitudinal Observational Study of Child Health

Sean CL Deoni, Jennifer
Beauchemin, Alexandra Volpe, Viren
D'Sa, the RESONANCE Consortium
medRxiv 2021.08.10.21261846; doi:
https://doi.org/10.1101/2021.08.10
.21261846

- Leveraging a large on-going longitudinal study of child neurodevelopment, we examined general childhood cognitive scores in 2020 and 2021 vs. the preceding decade, 2011-2019.
- We find that children born during the pandemic have significantly reduced verbal, motor, and overall cognitive performance compared to children born pre-pandemic.
- Moreover, we find that males and children in lower socioeconomic families have been most affected.
- Results highlight that even in the absence of direct SARS-CoV-2 infection and COVID-19 illness, the environmental changes associated COVID-19 pandemic is significantly and negatively affecting infant and child development.

TAKE AWAY WHAT HARMS

GIVE WHAT HEALS



Diversity in gut flora promotes health

Wide varieties of different types of gut flora are associated with less chronic disease later

Feeding your kids whole foods from nature and including fermented foods like pickles, kiefer, kombucha, sauerkraut, and miso leads to gut flora diversity

Diversity in kids and cultures




The first
Thousand
days



KIDS HAVE
RESILIENT
INNATE IMMUNE
SYSTEMS



Two Branches of Immune Defense



Innate Immunity

- invariant (generalized)
- early, limited specificity
- the first line of defense
- 1. Barriers skin, tears
- 2. Phagocytes neutrophils, macrophages
- 3. Cells that release inflammatory mediators
- 4. Natural Killer cells
- 5. Complement and proteins

Adaptive Immunity

- variable (custom)
- later, highly specific
- "remembers" infection
- 1. APCs (Antigen Presenting Cells)present Ag to T cells
- 2. Activated T cells provide help to B cells and kill abnormal and infected cells
- 3. B cells produce antibody specific for antigen



Childhood COVID deaths compared to bikes, cars, and suicide

- In seven countries (the US, UK, Italy, Spain, France, Germany and South Korea), the death rate from COVID in pediatric patients was 1.7 per 1 million.
- •COVID 19 deaths in children analyzed up until February 2021 comprise 0.48% of total mortality from all causes in a normal year.
- COVID 19 deaths in children update July 2021: comprise 0.6% of all cause pediatric mortality
 - Bhopal, Sunil S, et al. "Children and Young People Remain at Low Risk of COVID-19 Mortality." The Lancet Child & Adolescent Health, vol. 5, no. 5, May 2021, pp. e12–e13, www.thelancet.com/action/showPdf?pii=S2352-4642%2821%2900066-3, 10.1016/s2352-4642(21)00066-3. Accessed 25 Apr. 2021.

Mortality data does not justify covid vax for healthy kids if there are NOT any signals of adverse events

- Causes of death (2018 data for comparison)
 - Transport accidents 14.6 per million
 - Suicides 9.4 per million (doubled during COVID lockdowns)
 - Cancer 13.5 per million
- In the 5-14 age group, risk of dying from or "with" COVID is 1 in a million
 - One study of 48,000 claims could not find a healthy child who died from COVID
 - Deaths occur in children with chronic illness, not in healthy kids who would get COVID 'vaccines'

Table. Age-Specific Mortality Rates (per Million) for COVID-19 (March-October 2020) and Other Leading Causes of Death (March-October 2018)^a

	Causes of death ^b										
Age, y					Unintentional injuries		Intentional injuries		Leading causes of infant deaths		
		Malignant neoplasms	Transport accidents		Accidental drug overdoses	Suicide	Homicide	Birth defects	Short gestation	SUID	
<1	7.4	51.6	8.6	2.9	15.5	1.6	0.0	46.7	773.7	682.2	603.4
1-4	1.0	4.8	13.1	2.0	17.5	0.3	0.0	15.6	15.9		4
5-14	1.0	2.7	13.5	2.0	14.6	0.4	9.4	4.7	6.4		
15-24	9.9	13.8	20.9	2.8	108.3	66.1	97.0	72.1	5.5		
25-34	38.6	52.1	53.7	4.2	113.2	220.7	120.9	78.8	6.4		
35-44	109.9	169.1	172.0	10.1	93.8	234.0	128.1	54.7	7.2		
45-54	294.8	509.7	597.5	56.1	100.7	208.2	140.3	33.9	11.2		
55-64	683.3	1239.8	1802.4	285.8	105.0	161.2	139.8	23.7	17.8		
65-74	1574.6	2516.9	3702.0	809.9	99.2	50.8	114.1	15.7	13.4		
75-84	3832.4	6478.5	6845.7	2117.3	129.9	16.0	129.6	13.2	14.9		
≥85	10 699.7	24 530.2	10 442.4	4278.4	139.1	14.7	133.4	13.3	31.2		
Total	698.8	1287.7	1219.8	307.5	89.2	122.3	102.3	39.0	19.4		

Abbreviations: COVID-19, coronavirus disease 2019; SUID, sudden unexpected infant death (including sudden infant death syndrome).

^b Causes of death are defined by *International Statistical Classification of Diseases and Related Health Problems* codes for heart disease (IOO-IO9, I11, I13, I2O-I51), malignant neoplasms (COO-C9), chronic lower respiratory disease (J4O-J47), transport accidents (injuries) (VO1-V99, Y85), accidental drug overdoses (X4O-X44), suicide (*UO3, X6O-X84, Y87.0), homicide (*UO1-*UO2, X85-YO9, Y87.1), birth defects (QOO-Q99), short gestation (PO5-PO8), and sudden unexpected infant death (R95, R99, W75).

2018 baseline Compared to 2020

JAMA December 17, 2020 Steven H. Woolf

Ages 5-14 1 in 1,000,000 From or with COVID

Suicides 9.4 per million

^a Table presents 8-month aggregate COVID-19 mortality rates during the period of March through October 2020⁵ and mortality rates for other causes during the period of March through October 2018, ⁴ the most recent year for which detailed cause-of-death data are available.

Summary COVID death rates 2020

- Overall deaths from COVID in kids under 18 in 2020=182 (8 in healthy kids)
- Overall number of COVID cases in kids under 18 in 2020=17.5 million (CDC estimate as of January 15, 2021)
- ➤ Death rate from COVID in kids under 18: 182/17.5M=0.0000104 or about 1:100,000 (includes chronically ill and no access to appropriate treatment)
- > Death rate from COVID in healthy kids under 18: 8/17.5M=0.00000046 or about 1 in 2.5 million



NATURAL **IMMUNITY** IS ROBUST & DURABLE & SUPERIOR




Most children have already had COVID*

If your child already has had chicken pox, we do not give a chicken pox vaccine

If your child has had COVID, they have natural immunity

Given the lack of long term safety data and potential significant side effects, FLCCC recommends against COVID shots for healthy kids

*89% of toddlers by June 2022



ORIGINAL ARTICLE Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 Yair Goldberg, Ph.D., Micha Mandel, Ph.D., Yinon M. Bar-On, M.Sc., Omri Bodenheimer, M.Sc., Laurence S, Freedman, Ph.D., Nachman Ash, M.D., Sharon Alroy-Preis, M.D., Amit Huppert, Ph.D., and Ron Milo, Ph.D. Figures/Media N Engl J Med 2022; 386:2201-2212 DOI: 10.1056/NEJMoa2118946 25 References Abstract NEJM CareerCenter BACKGROUND PHYSICIAN IOBS Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provides natural immunity against reinfection. Recent studies have shown waning of the immunity provided by the Pediatrics, General Loma Linda, California BNT162b2 vaccine. The time course of natural and hybrid immunity is unknown. Academic Pediatric Neuropsychologist in Southern California Phoenix Arizona Hematology / Oncology Using the Israeli Ministry of Health database, we extracted data for August and September 2021, when Hematologists and Site Medical Directors, Hematology and the B.1.617.2 (delta) variant was predominant, on all persons who had been previously infected with Hematopoietic Cell Transplant SARS-CoV-2 or who had received coronavirus 2019 vaccine. We used Poisson regression with adjustment Brownsville Texa for confounding factors to compare the rates of infection as a function of time since the last immunity-Outpatient Primary Care Physician - Wellmed - Brownsville, TX conferring event.

Natural Immunity Superior and Longer Lasting than "Vaccine" induced immunity

- Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19: Jennifer L. Alejo et al, JAMA. Feb 3 2022;327(11):1085-1087. doi:10.1001/jama.2022.1393
 - Evidence of natural immunity in unvaccinated healthy US adults (NOT KIDS) up to 20 months
 - In some age groups in children, vaccine induced antibodies only last 5 weeks
- Past SARS-CoV-2 infection protection against re-infection: a systematic review and metaanalysis. Lancet Feb 16, 2023. https://doi.org/10.1016/S0140-6736(22)02465-5
 - "We identified a total of 65 studies from 19 different countries. Our meta-analyses showed that protection from past infection and any symptomatic disease was high for ancestral, alpha, beta, and delta variants, but was substantially lower for the omicron BA.1 variant."
- Evolutionary biology show pattern of viral variants becoming less severe with time

HEALTHY CHILDREN SURVIVE **COVID ALMOST ALL THE TIME**



CHILDREN SURVIVE COVID 99.997% OF THE TIME



Why are children at less risk of bad outcomes?


Some possibilities

- 1. Children have excellent innate immune systems
- 2. Children are less likely to mount an immune over-reaction to COVID
- 3. Children have fewer ACE-2 receptors for the COVID virus to bind to*
- 4. Children have fewer co-morbidities than adults



*Bunyavanich, Supinda, Anh Do, and Alfin Vicencio. "Nasal gene expression of angiotensin-converting enzyme 2 in children and adults." *JAMA* 323, no. 23 (2020): 2427-2429.

More than ½ of U.S. children have at least one chronic health condition




AVOID SIDE EFFECTS BY NOT GIVING AN UNNECESSARY VACCINE



Putting vaccine benefits in perspective

Death from Common Infectious Diseases Declined 90% BEFORE Vaccines Were Introduced*




Source:

Journal of American Academy of Pediatrics, December 2000


How to recognize a vaccine injury

- Temporality
 - Distinguishing "normal" reactions from concerning
 - Onset of reactions based on type of vaccine
 - DPAT: first 48-72 hours
 - MMR and varicella: 7-12 days
- Plausible mechanism of action
 - High index of suspicion for immune activation syndromes
- New onset of symptoms
 - Neurologic changes: encephalopathic cry, internal vibrations, paresthesias
 - Changes in GI patterns
 - Regression of milestones
 - Immune dysregulation: new eczema, new asthma, etc.






Temporal correlation with injections Historical comparison to all prior vaccines Excess mortality




BRADFORD HILLS CRITERIA OF CAUSATION





Any protection from the vaccine against COVID symptoms wanes in several months

- Vaccine efficacy drops by 2-3 months
- Then the vaccinated are more likely to get symptomatic infection than the unvaccinated
 - Negative efficacy



Duration of immune protection in unvax'd with primary COVID infection: Qatar study

97.3%


Duration of protection from vaccine drops quickly in pediatric population

Efficacy wanes after 3-4 months

Pediatric studies only lasted 60 days

NY Health Dept data:

12% protection at 5 weeks after jab in 5-12 yo





VACCINES ARE NOT TESTED AGAINST TRUE PLACEBOS (inert saline)

Unlike drugs, which are required to be safety tested against an inert placebo, vaccines fall under the category of "biologics" and are not tested against an inert saline placebo.

As an example, Merck's HPV vaccine was tested against a dangerous aluminum adjuvant that can trigger autoimmune disorders and not against an inert saline placebo.



A SAFE VACCINE WOULD BE TESTED FOR A LONG ENOUGH PERIOD TO PROPERLY TRACK ADVERSE EVENTS. In addition, post approval surveillance would be conducted to measure long-term effects.

Most vaccines are only monitored for side effects for a period of 2 to 5 days, as stated on the vaccine insert literature and can take months to years to be detected.

Autoimmune, neurodevelopmental, and chronic conditions can take months or years to be detected.

As an example, Merck's hepatitis B vaccine given to one-day-old infants was only safety tested for 5 days.



COVID vaccines for kids under 6 won't have to meet FDA 50% efficacy standard

- The FDA's top vaccine official told a congressional committee on May 6, 2022 that COVID-19 vaccines for kids under 6 will not have to meet the agency's 50% efficacy threshold for blocking symptomatic infections required to obtain Emergency Use Authorization.
- "If these vaccines seem to be mirroring efficacy in adults and just seem to be less effective against Omicron like they are for adults, we will probably still authorize," Dr. Peter Marks, director of the Center for Biologics Evaluation and Research at the FDA told the House Select Subcommittee on the Coronavirus Crisis.

Shortcomings of Pfizer trials COVID vax for children: use of "immunobridging"

- "Approval for the COVID vaccines in infants and toddlers is based on two trials that used changes in antibody levels as an estimate of efficacy, but did not assess protection from severe disease, hospitalization or multisystem inflammatory syndrome in children (MIS-C), important outcomes that parents worry about.
- "In a Food and Drug Administration (FDA) meeting on June 28, Pfizer Vice President for Viral Vaccines, Kena Swanson conceded that 'there is no established correlate' between antibody levels and protection from disease.
- "In the Pfizer trial, the **confidence interval** which shows the possible range of protection level was **alarmingly wide**, with the lower bound suggesting the possibility of a 380% increase in the chance of infection after the third dose.

Limitations of the clinical study: Pfizer/biontech Kids

Outcome	Importance ^a	Description
Benefits		
Symptomatic lab-confirmed COVID-19	Critical	Current studies use PCR + specific symptoms; immunobridging
Hospitalization due to COVID 19	Important	Phase 3 trials not designed to detect statistical differences between treatment groups for this outcome
Multisystem inflammatory syndrome in children (MIS-5)	Important	Phase 3 trials not designed to detect statistical differences between treatment groups for this outcome
SARS-CoV-2 seroconversio	Important	Measured using antibodies to non-spike protein to differentiate eroconversion due to natural infection from immunogenicity to vaccine; no data available
Asymptomatic SARS-CoV-2 infection	Important	Measured using serial PCR; no data available

Pfizer/biontech: Kids trial results based on ~1000 children in each arm of trial

Summary:

- Conclusions based on only 16 cases of clinical COVID
- No results on reducing hospitalizations or deaths
- No results on reducing Multisystem Inflammatory Syndrome-C (although MIS-C was a big justification for using the vaccine in this age group)
- No results on formation of antibodies, or prevention of carriers
- No results to prove decreased transmission to others

Shortcomings of Pfizer trial in children

- "The protocol was changed mid-trial:
 - The original two-dose schedule exhibited poor immunogenicity with efficacy far below the required standard.
 - A third dose was added by which time many of the original placebo recipients had been vaccinated."

Shortcomings

- Pediatric patients only tested for COVID if symptomatic
 - So do not even know true infection rate
- 3,000 of the 4,526 children (aged 6 months through 4 years) enrolled in Pfizer's pediatric COVID trial were excluded without explanation.
- Oftentimes, trial participants drop out or are excluded due to severe side effects. Here, we don't know why two-thirds of the participants were eliminated
 - In my medical school classes about how to analyze research, a 66% dropout rate should have been sufficient to deem the trial null and void

When Maddie was 12 years old, she heard about the Pfizer vaccine trials at Cincinnati's Children's Hospital and told her parents she wanted to sign up as a test subject. Her brother, Lucas, also volunteered.

- Maddie is now paralyzed from the waist down.
- She has gastroparesis with great difficulty swallowing food and water.
- Maddie needs a wheelchair or walker to get around, and a feeding tube for nourishment.
- At one point, Maddie was having 20 or more blackout/fainting episodes per day.





12 -15 ADOLESCENT TRIAL FAILURE TO REPORT SERIOUS ADVERSE EVENTS

Maddie de Garay is a 12 year old trial participant who developed a <u>serious reaction</u> after her second dose and was hospitalized within 24 hours.

Maddie developed gastroparesis, nausea and vomiting, erratic blood pressure, memory loss, brain fog, headaches, dizziness, fainting, seizures, verbal and motor tics, menstrual cycle issues, lost feeling from the waist down, lost bowel and bladder control and had an nasogastric tube placed because she lost her ability to eat. She has been hospitalized many times, and for the past 10 months she has been wheelchair bound and fed via tube.

In their report to the FDA, **Pfizer described her** injuries as "functional abdominal pain."

 One participant experienced an SAE reported as generalized neuralgia, and also reported 3 concurrent non-serious AEs (abdominal pain, abscess, gastritis) and 1 concurrent SAE (constipation) within the same week. The participant was eventually diagnosed with functional abdominal pain. The event was reported as ongoing at the time of the cutoff date.



THERE IS NO **LONG TERM** SAFETY DATA; SHORT TERM DATA IS WORRISOME



Pfizer original trials eliminated the control groups



After 2 months, the placebo group in the original trial was offered the COVID vaccine and most took it

So we do not have long term follow up on the ~22,000 people who were to be the controls for long term differences in the health of vaxxed/unvaxxed


In the initial pediatric trial, no long term comparisons of overall health or all cause mortality can be made In the pediatric trials, control group eliminated after 6 months



CDC removes statement about mRNA being broken down in a few days and spike protein leaving in a few weeks.

web.archive.org/web/20220722133644/https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html

web.archive.org/web/20220723161304/https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html



Myocarditis and COVID mRNA vax

In the 12- to 17-year-old male cohort, the risk of myo/pericarditis is at least 11 times higher than the background rate.



Age groups	Females			Males		
	Doses admin	Expected'	Observed	Doses admin	Espected'	Observed
12-17 yrs	2,189,726	1-7	20	2,039,871	1-12	132
18-24 yrs	5,237,262	2-18	27	4,337,287	2-25	233
25-29 yrs	4,151,975	1-15	11	3,625,574	2-21	69
30-39 yrs	9,356,296	5-54	14	8,311,301	5-48	71
40-49 yrs	9,927,773	6-57	23	8,577,766	5-49	40
50-64 yrs	18,695,450	11-108	25	16,255,927	9-94	34
65+ yrs	21,708,975	12-125	17	18,041,547	10-104	16
Not reported	-	-	1	-	-	9

[&]quot;a kinder, gentler, milder myocarditis"







Happy Baby Lawsuit Toxic Heavy Metals



APRIL 2023
3 former execs arrested and charged for marketing faulty lead testing devices



"Stirring \ldots [a] blueprint for all those who believe \ldots that 'the world \ldots



What the Eyes Don't See



A STORY OF CRISIS, RESISTANCE, AND HOPE IN AN AMERICAN CITY

Mona Hanna-Attisha




"Revealing, with the gripping intrigue of a Grisham thriller."

—O: THE OPRAH MAGAZINE

"Safe and effective"







The FDA and CDC's Vaccine Adverse Event Reporting System (VAERS) has documented over 825,000 Covid-19 vaccine adverse events reports in the United States alone. According to a study out of Harvard University, VAERS reports are thought to only represent only approximately 1% of the actual number of Covid-19 vaccine adverse events.

References: 1) Openvaers website: https://openvaers.com/covid-data 2) https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf

06/15/22 CHILDREN'S HEALTH DEFENSE

The Evidence Is Clear: Healthy Children Simply Don't Need COVID Vaccines: Dr. David Gortler

TRUE INFORMED CONSENT **FOR PARENTS** TO DECIDE FOR CHILDREN



True Informed Consent

- All medical decisions require a **full disclosure of risks, benefits** and alternatives to treatment, and an individualized risk-benefit analysis, in a sober discussion between a qualified healthcare professional and the patient, or parent/guardian of a child under 16 (the legal age of consent).
- Nuremburg code specifically forbids coercion or bribery.
 - Use of peer pressure
 - Gift cards, pizza parties, donuts, etc.





I CARE PEDIATRIC PROTOCOLS



KID'S I CARE PROTOCOL

Vitamin D Vitamin C **Vitamin A**

Zinc

Ibuprofen

Quercetin

Probiotics

Ivermectin Melatonin

Essential oils

I-CARE

FOR KIDS



Download I-CARE For Kids Summary



Download I-CARE For Kids Protocol

A Parent's Guide to Prevention and Early COVID Treatment for Children

Most children with COVID-19 handle the virus well and recover fully. Despite a lot of fearmongering, COVID is not a deadly disease for most children. In fact, data show that the death rate is extremely low in patients under 17 years old. This guide aims to help you understand the real risks and know how to respond. The best thing you can do is focus on making sure your child is healthy overall and that their immune system is strong and robust.

Recommended Therapies

Dosage varies based on size and age of child; see I-CARE For Kids protocol for full details

Vitamin D: Adequate Vitamin D levels help our bodies fight inflammation and boosts immunity.

Vitamin C: An excellent antiviral that protects against a wide variety of viruses including COVID-19.

Vitamin A: Found in red, yellow, and orange vegetables and a main component in cod liver oil.

Zinc: Strengthens innate and adaptive immunity and inhibits the virus from entering cells.

Ibuprofen: Reduces fever, treats aches, and fights inflammation. Do not use for low-grade fever.


Quercetin: Kills the virus, and is a potent antioxidant and anti-inflammatory.

Probiotics: Helps train the immune system to attack pathogens (rather than itself).

Ivermectin: Clinical experience shows ivermectin to be safe and effective in children.

Melatonin: A potent antioxidant with important anti-inflammatory effects. Essential oils: Do not ingest; diffuse in the room or apply topically to the skin.

IONOPhore: a substance which is able to transport particular ions across a lipid membrane in a cell.



More aggressive treatment for children with chronic diseases

Hydroxychloroquine: Not needed in most cases; decision to use in selected high-risk individuals would involve informed consent discussions between the clinician and family.

Azithromycin: Acts as a zinc ionophore; little in the published literature about COVID and azithromycin and children.

Asthma medications: Children with asthma are at higher risk of complications from COVID infection. When COVID is circulating, it is wise to make sure that your asthmatic child keeps taking any controller medications (such as inhaled steroids) and has refills of any rescue medications (like albuterol).

N-acetyl cysteine (NAC): Helps promote detoxification.

Omega-3 essential fatty acids: Excellent anti-inflammatories.

Mouthwashes and nasal sprays: Have not been studied in children with SARS-CoV2.

Not routinely recommended

- Acetaminophen in repeated doses
- Antihistamines
- Antibiotics early in the illness
- Decongestants
- Cough suppressants
- Aspirin for fever

QUECERTIN

- Food sources: fruits, veggies, seeds, grains, kale, red onions
 - Rapidly cleared with 1-2 hour half life after food
- Mast cell stabilizer: role in allergic, inflammatory and autoimmune diseases which release IL 8 & TNF alpha
- Also anti-clotting mechanism
- Therapeutic effects enhanced when given with Vitamin C
- Doses:
 - Toddlers: up to 250 mg bid
 - Elementary: up to 500 bid
 - Adolescents 400-600 mg up to tid

MELATONIN


- Beyond sleep excellent anti-oxidant (independent of M1 and M2 receptors that are important for sleep induction)
- Regulation of mood, learning, memory and immune activity
- Doses:
 - Not recommended in babies who are still establishing sleep/wake rhythms
 - most toddlers do well with between 0.5 and 3 mg
 - In special circumstances, we use 5-10 mg
- Pediatric limitations on long acting forms
 - If kids cannot swallow pill without chewing, hard to use long acting forms
 - Some kids have rebound waking between 2-3 am vivid nightmares

FAMOTIDINE: H2 receptor antagonist

- Approved in infants down to 1 month of age
- Dose 0.5 1 mg/kg/day q day or divided bid
- Caution with alpha gal patients: pill form has mag stearate, which sometimes has mammal products, sometimes not
- Caution in pregnancy and breastfeeding but good R:B ratio IMO
 - Pregnancy: animal studies showed problems only at >250 times human doses
 - Breastfeeding: animal studies showed growth suppression at 600 times human doses




Varied conditions share the same set of root causes




Principles for treating vaccine injury

- Treating Oxidative Stress
- Optimizing detoxification strategies
- Balancing immune dysregulation
- Supporting mitochondrial function
- Correcting dysfunctional metabolism
- Restoring optimal gut function



BASED ON SCIENTIFIC **EVIDENCE, COVID 'VACCINES'** ARE NOT INDICATED IN PEDIATRIC **PATIENTS**






ACIP recs April 2023

able 1. COVID-19 vaccination schedule for people who are NOT moderately or severely immunocompromised by COVID-19 vaccination history, April 2023: Ages 6 months—4 years

COVID-19 vaccination history	Bivalent vaccine	Number of bivalent doses indicated	Dosage (mL/ug)	Vaccine vial cap and label colors	Interval between doses
	Moderna or	2	0.25 mL/25 ug	Dark blue cap; gray label border	Dose 1 and Dose 2: 4–8 weeks
Unvaccinated	Pfizer BioNTech	3	0.2 mL/3 ug	Maroon	Dose 1 and Dose 2: 3–8 weeks Dose 2 and dose 3: At least 8 weeks
1 dose monovalent Moderna	Moderna	1	0.25 mL/25 ug	Dark blue cap; gray label border	4-8 weeks after monovalent dose
2 doses monovalent Moderna	Moderna	1	0.2 mL/10 ug	Dark pink cap; yellow label border	At least 8 weeks after last monovalent dose
2 doses monovalent Moderna and 1 dose bivalent Moderna	NA; previously received 1 bivalent vaccine dose	NA	NA	NA	NA
1 dose monovalent Pfizer- BioNTech	Pfizer BioNTech	2	0.2 mL/3 ug	Maroon	Dose 1: 3–8 weeks after monovalent dose Dose 1 and Dose 2: At least 8 weeks
2 doses monovalent Pfizer- BioNTech	Pfizer BioNTech	1	0.2 mL/3 ug	Maroon	At least 8 weeks after last monovalent dose
3 doses monovalent Pfizer- BioNTech	Pfizer BioNTech	1	0.2 mL/3 ug	Maroon	At least 8 weeks after last monovalent dose
2 doses monovalent Pfizer- BioNTech and 1 dose bivalent Pfizer-BioNTech	NA; previously received 1 bivalent vaccine dose	NA	NA	NA	NA

ACIP recs April 2023 vs. Mumper recs

- Since the risk of disease is minimal, any vaccine should have minimal side effects
- Even rare side effects will affect lots of children if a new injection is deployed widely



Additional help for providers is on the way

Wisdom vs. Knowledge

It ain't what you don't know that gets you into trouble. It's what you know for sure that just ain't so.



Mark Twain

American Author and Humorist

(1835-1910)

